But the activities of such agents would be expected to combine favorably with current HER2 kinase inhibitors, and the combination may provide the requisite potency to fully and durably inhibit HER2-HER3 signaling in HER2-amplified cancers, a task that is beyond the therapeutic index of current modalities. The gene discussed is ERBB3; the disease is cancer.